i&i Bio is a venture capital firm based in Luxembourg that invests in European life sciences companies focused on drug discovery, medical devices, diagnostics and digital health.
Jaromir serves as a board member at the European Innovation Council and SMEs Executive Agency alongside his role as CEO of i&i Biotech Fund. He brings venture building and business development experience, having previously directed business development at i&i Prague.
The financing round was led by Soulmates Ventures with backing from several new and existing investors.
"Antiverse is tackling one of the most technically demanding problems in drug discovery. The team’s ability to reduce the development time for de novo therapeutic-grade antibodies in a defined domain to under four months is a significant scientific and operational achievement. This capability, combined with the AI-driven design and in-house labs, positions Antiverse on track to become a global leader and the go-to developer of antibody therapies for the most elusive disease targets in medicine"
The latest investment brings total equity financing to £7.2m and will support clinical progression of internal assets.
"A third of all FDA-approved drugs target GPCRs, yet, despite decades of research and billions of funding, only a few GPCR-targeting antibodies exist. Thanks to the support of our investors, we are one step closer to making GPCRs and other challenging targets druggable, bringing needed therapies to patients across the globe."
.png)
